We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+0.45%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.08B
AUM Growth
-$169M
Cap. Flow
-$29.6M
Cap. Flow %
-1.42%
Top 10 Hldgs %
77.47%
Holding
49
New
4
Increased
17
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$61.2M
2
EPZM
Epizyme, Inc
EPZM
+$41.5M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$36.3M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$24.1M
5
UTHR icon
United Therapeutics
UTHR
+$13.5M

Top Sells

Rank Stock Value
1
THOR
THORATEC CORPORATION
THOR
+$136M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.4M
3
CYBX
CYBERONICS INC
CYBX
+$24.5M
4
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$12.3M
5
ENDP
Endo International plc
ENDP
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 72.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARIA
26
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$13M 0.63%
2,231,717
– –
RIGL icon
27
Rigel Pharmaceuticals
RIGL
$782M
$12.8M 0.61%
517,632
– –
HTWR
28
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$12.8M 0.61%
243,868
– –
AIMT
29
DELISTED
Aimmune Therapeutics
AIMT
$8.24M 0.4%
+325,599
New +$7.61M
EXAS
30
DELISTED
Exact Sciences
EXAS
$7.06M 0.34%
392,676
– –
ALIM
31
DELISTED
Alimera Sciences
ALIM
$6.66M 0.32%
200,920
– –
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.65M 0.27%
33,214
+28,898
+670% +$10.4M
TLPH icon
33
Talphera
TLPH
$72.7M
$5.05M 0.24%
82,832
-23,955
-22% -$1.97M
ACGN
34
DELISTED
Aceragen Inc
ACGN
$4.21M 0.2%
9,257
+228
+3% +$101K
OREX
35
DELISTED
Orexigen Therapeutics, Inc.
OREX
$4.08M 0.2%
193,132
– –
DRNA
36
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.2M 0.11%
267,890
+197,184
+279% +$2.28M
OCGN icon
37
Ocugen
OCGN
$475M
$1.81M 0.09%
7,576
– –
ALGN icon
38
Align Technology
ALGN
$12.4B
$1.57M 0.08%
27,757
– –
ARCT icon
39
Arcturus Therapeutics
ARCT
$216M
$1.53M 0.07%
36,313
+13,943
+62% +$733K
PGEN icon
40
Precigen
PGEN
$2.45B
$1.5M 0.07%
47,524
– –
BSTC
41
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.27M 0.06%
29,257
-21,179
-42% -$1.14M
CYTK icon
42
Cytokinetics
CYTK
$10.5B
$827K 0.04%
123,686
– –
XOMA
43
DELISTED
Xoma
XOMA
$601K 0.03%
39,950
– –
MRNS
44
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$492K 0.02%
+14,754
New +$833K
QURE icon
45
uniQure
QURE
$3.13B
$418K 0.02%
+20,453
New +$539K
ZGNX
46
DELISTED
Zogenix, Inc.
ZGNX
$375K 0.02%
+27,800
New +$501K
SPHS
47
DELISTED
Sophiris Bio, Inc.
SPHS
$163K 0.01%
191,600
– –
MNK
48
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-3,588
Closed -$422K
CYBX
49
DELISTED
CYBERONICS INC
CYBX
– –
-412,000
Closed -$24.5M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q3 2015 Portfolio in Review

As of Q3 2015, Palo Alto Investors held 49 positions worth $2.08B, down 7.5% from $2.25B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Palo Alto Investors's Q3 2015 filing shows 4 new, 17 increased, 7 reduced and 2 closed positions. Its largest new stake was Aimmune Therapeutics: 325,599 shares worth $8.24M. The largest sale was THORATEC CORPORATION, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier.

  • Palo Alto Investors's largest Q3 2015 buy was Aimmune Therapeutics: 325,599 shares worth $8.24M.
  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q3 2015, an estimated $61.2M increase.
  • Palo Alto Investors's biggest Q3 2015 reduction was THORATEC CORPORATION, cutting an estimated $136M.
  • Palo Alto Investors fully exited CYBERONICS INC in Q3 2015, selling an estimated $24.5M.
  • Palo Alto Investors's ten largest holdings make up 77% of its $2.08B portfolio in Q3 2015.
  • Palo Alto Investors opened 4 new positions and closed 2 in Q3 2015.
  • Palo Alto Investors's portfolio value fell 7.5% quarter-over-quarter to $2.08B.

Based on Palo Alto Investors's 13F filing for Q3 2015, filed 16 Nov 2015.